Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.47 |
| ▸ | HPGD | P15428 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 7/20 | 0.42 |
| ▸ | HTT | P42858 | 4/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 3/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3816951 | 0.98 | KDM4E (0.46) | KDM4EHPGDALDH1A1HSD17B10TSHR | |
| SCHEMBL3815499 | 0.91 | LMNA (0.50) | KDM4EHPGDALDH1A1HSD17B10TSHR | |
| SCHEMBL13812118 | 0.83 | KDM4E (0.51) | KDM4EHPGDALDH1A1HSD17B10TSHR | |
| SCHEMBL13799071 | 0.83 | KDM4E (0.54) | KDM4EHPGDALDH1A1HSD17B10TSHR | |
| SCHEMBL3813878 | 0.81 | KDM4E (0.53) | KDM4EHPGDALDH1A1HSD17B10TSHR | |
| SCHEMBL3812661 | 0.81 | KDM4E (0.48) | KDM4EHPGDALDH1A1HSD17B10TSHR | |
| Trifluoroacetic Acid SCHEMBL3815453 | 0.81 | KDM4E (0.50) | KDM4EHPGDALDH1A1HSD17B10TSHR | |
| SCHEMBL4171976 | 0.80 | KDM4E (0.48) | KDM4EHPGDALDH1A1HSD17B10TSHR | |
| SCHEMBL4171969 | 0.80 | KDM4E (0.48) | KDM4EHPGDALDH1A1HSD17B10TSHR | |
| SCHEMBL13997404 | 0.80 | HTT (0.44) | KDM4EHPGDHSD17B10RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756135-B1 | ESTER LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS | GLAXOSMITHKLINE ZAGREB (HR) | 2009-08-12 | — | — | EP | disclosed |
| US-7547679-B2 | Ether linked macrolides useful for the treatment of microbial infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O (HR) | 2009-06-16 | — | — | US | disclosed |
| US-7547679-B2 | Ether linked macrolides useful for the treatment of microbial infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O (HR) | 2009-06-16 | — | — | US | disclosed |
| US-20080312167-A1 | 4'' Amino Linked Macrolides Useful for the Treatment of Microbial Infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR (HR) | 2008-12-18 | — | — | US | disclosed |
| US-20080312167-A1 | 4'' Amino Linked Macrolides Useful for the Treatment of Microbial Infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR (HR) | 2008-12-18 | — | — | US | disclosed |
| US-20080255060-A1 | Ester Linked Macrolides Useful For The Treatment of Microbial Infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB (HR) | 2008-10-16 | — | — | US | disclosed |
| US-20080255060-A1 | Ester Linked Macrolides Useful For The Treatment of Microbial Infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB (HR) | 2008-10-16 | — | — | US | disclosed |
| US-20080249033-A1 | Carbamate Linked Macrolides Useful For The Treatment Of Microbial Infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O. (HR) | 2008-10-09 | — | — | US | disclosed |
| US-20080249033-A1 | Carbamate Linked Macrolides Useful For The Treatment Of Microbial Infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O. (HR) | 2008-10-09 | — | — | US | disclosed |
| EP-1879903-A1 | ETHER LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS | GlaxoSmithKline istrazivacki centar Zagreb d.o.o. (HR) | 2008-01-23 | — | — | EP | disclosed |
| EP-1879904-A1 | 4\" AMINO LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS | GlaxoSmithKline istrazivacki centar Zagreb d.o.o. (HR) | 2008-01-23 | — | — | EP | disclosed |
| EP-1756134-A1 | CARBAMATE LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS | GlaxoSmithKline istrazivacki centar Zagreb d.o.o. (HR) | 2007-02-28 | — | — | EP | disclosed |
| EP-1756135-A1 | ESTER LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS | GlaxoSmithKline istrazivacki centar Zagreb d.o.o. (HR) | 2007-02-28 | — | — | EP | disclosed |
| WO-2006120541-A1 | ETHER LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006120545-A1 | 4' AMINO LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2006-11-16 | — | — | WO | disclosed |
| US-20060258600-A1 | 14- or 15-Membered macrolides substituted at the 4'' position such as 4''-O-[2-(2-{2-[2-(3-Carboxy-7-chloro-1-cyclopropyl-4-oxo-1,4-dihydro-quinolin-6-ylamino)-ethoxy]-ethoxy}-ethylamino)-ethyl]-azithromycin 11,12-cyclic carbonate; therapy or prophylaxis of systemic or topical microbial infections | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2006-11-16 | — | — | US | disclosed |
| WO-2005108412-A1 | ESTER LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (US) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005108413-A1 | CARBAMATE LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255060-A1 | Ester Linked Macrolides Useful For The Treatment of Microbial Infections | CYP51A1, TLR5, MALT1 | KDM4E 2612/4885HPGD 1842/4885ALDH1A1 2370/4885 |
| US-20060258600-A1 | 14- or 15-Membered macrolides substituted at the 4'' position such as 4''-O-[2-(2-{2-[2-(3-Carboxy-7-chloro-1-cyclopropyl-4-oxo-1,4-dihydro-quinolin-6-ylamino)-ethoxy]-ethoxy}-ethylamino)-ethyl]-azithromycin 11,12-cyclic carbonate; therapy or prophylaxis of systemic or topical microbial infections | IL17A, IL15, CASP14 | KDM4E 1422/4885HPGD 1966/4885ALDH1A1 3802/4885 |
| US-20080312167-A1 | 4'' Amino Linked Macrolides Useful for the Treatment of Microbial Infections | IL4I1, IL4, TLR5 | KDM4E 1535/4885HPGD 2512/4885ALDH1A1 2548/4885 |
| US-20080249033-A1 | Carbamate Linked Macrolides Useful For The Treatment Of Microbial Infections | CYP51A1, CUTA, MALT1 | KDM4E 620/4885HPGD 3347/4885ALDH1A1 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.